Face-Off: Team Cubs vs Team White Sox: May 31, 2025

home / face-off / face-off-team-cubs-vs-team-white-sox-may-31-2025

Panelists discuss various aspects of lower-risk myelodysplastic syndromes, including trial results on erythropoiesis-stimulating agent timing and novel agents like luspatercept and imetelstat, treatment sequencing and timing debates, personalized approaches based on erythropoietin levels, and complex case management balancing immediate symptom relief with long-term strategies.

Early vs Late Onset of ESA in LR-MDS: Results From Phase 3 EPO-PRETAR Trial

EP. 1: Early vs Late Onset of ESA in LR-MDS: Results From Phase 3 EPO-PRETAR Trial

Thomas W. LeBlanc, MD, MA;Guru Subramanian Guru Murthy, MD, MS; Raji Shameem, MD;Daniel DeAngelo, MD, PhD;Rafael Madero-Marroquin, MD;Mikkael A. Sekeres, MD, MS
June 24th 2025

Panelists discuss the results of the phase 3 EPO-PRETAR trial in a dynamic, debate-style forum on lower-risk myelodysplastic syndromes, weighing the benefits of early vs late erythropoiesis-stimulating agent initiation while highlighting the need for more patient-centered outcome measures.

COMMANDS and ELEMENT-MDS Trials: Long-Term Analysis, Survival, Duration of Response, and Hemoglobin Levels

EP. 2: COMMANDS and ELEMENT-MDS Trials: Long-Term Analysis, Survival, Duration of Response, and Hemoglobin Levels

Thomas W. LeBlanc, MD, MA;Guru Subramanian Guru Murthy, MD, MS; Raji Shameem, MD;Daniel DeAngelo, MD, PhD;Rafael Madero-Marroquin, MD;Mikkael A. Sekeres, MD, MS
June 24th 2025

Panelists discuss long-term results from a phase 3 trial comparing luspatercept and epoetin alfa in lower-risk MDS, highlighting luspatercept’s superior efficacy in achieving sustained transfusion independence and the need for further research on earlier intervention strategies.